Antitumor activity of a medium-chain triglyceride solution of the angiogenesis inhibitor TNP-470 (AGM-1470) when administered via the hepatic artery to rats bearing Walker 256 carcinosarcoma in the liver.
The antitumor effect of an angiogenesis inhibitor, TNP-470 (AGM-1470, 6-0-(N-chloroacetylcarbamoyl)-fumagillol), administered via the hepatic artery in a medium-chain triglyceride (MCT) solution, in which TNP-470 is very stable, was examined in rats bearing Walker 256 carcinosarcoma in the liver. The MCT solution containing 0.1 mg of TNP-470 completely suppressed tumor growth after a single arterial injection, and the solutions containing 0.5 approximately 5 mg of TNP-470 caused tumor regression function. These antitumor effects lasted for at least 2 weeks. Moreover, the administration of the MCT solution containing 5 mg of TNP-470 also caused remarkable regression of well-developed enlarged tumors 2 weeks after inoculation, indicating potential in the treatment of unresectable hepatic cancer. When the MCT solution containing radiolabeled TNP-470 was injected via the hepatic artery, the initial radioactivity in the tumor was 22 times that in the normal part of the liver and 5.7 times that in the tumor when an aqueous solution of radiolabeled TNP-470 was injected. Also, in the case of the MCT solution, the radioactivity in the tumor was maintained at a relatively high level for over 2 weeks after injection. These results indicate that the remarkable antitumor effect resulted from the selective delivery and prolonged retention of TNP-470 at the tumor site.
Yanai
S
S
DDS Research Laboratories, Pharmaceutical Research Division, Takeda Chemical Industries, Osaka, Japan.
Okada
H
H
Misaki
M
M
Saito
K
K
Kuge
Y
Y
Ogawa
Y
Y
Toguchi
H
H
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D002279:Carcinoma 256, Walker / Q000188:drug therapy*; D003510:Cyclohexanes; D006499:Hepatic Artery; D007269:Injections, Intra-Arterial; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy*; D008297:Male; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014280:Triglycerides / Q000008:administration & dosage / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D012717:Sesquiterpenes; D014280:Triglycerides; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000077609:O-(Chloroacetylcarbamoyl)fumagillol